Inventor · disambiguated record
Ralf Hosse
Also filed as: HOSSE RALF · HOSSE RALF JÖRG
49 granted patents·40 pending applications·798 citations·filing 2004–2024
98Inventor score
Top patents by PatentIndex Score
89 records- 0198US11130822B2ImmunoconjugatesROCHE GLYCART AG·Filed 2019·Granted Sep 28, 2021·16 cites·24 claims
- 0298US10316104B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Jun 11, 2019·30 cites·23 claims
- 0398US10202464B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Feb 12, 2019·30 cites·3 claims
- 0498US10184009B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2017·Granted Jan 22, 2019·37 cites·30 claims
- 0598US9447159B2ImmunoconjugatesAST OLIVER·Filed 2012·Granted Sep 20, 2016·111 cites·27 claims
- 0697US10577429B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2015·Granted Mar 3, 2020·17 cites·28 claims
- 0797US10323098B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2016·Granted Jun 18, 2019·25 cites·30 claims
- 0897US10253110B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2015·Granted Apr 9, 2019·15 cites·17 claims
- 0997US9266938B2Mutant interleukin-2 polypeptidesAST OLIVER·Filed 2012·Granted Feb 23, 2016·123 cites·25 claims
- 1096US11111312B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2018·Granted Sep 7, 2021·8 cites·5 claims
- 1196US9206260B2Anti-CEA antibodiesROCHE GLYCART AG·Filed 2013·Granted Dec 8, 2015·23 cites·13 claims
- 1295US11780920B2Antibodies binding to CD3 and CD19HOFFMANN LA ROCHE·Filed 2021·Granted Oct 10, 2023·4 cites·59 claims
- 1395US10526413B2Bispecific antibodies specific for OX40HOFFMANN LA ROCHE·Filed 2016·Granted Jan 7, 2020·23 cites·20 claims
- 1495US9346872B2Interleukin-10 fusion proteinsROCHE GLYCART AG·Filed 2013·Granted May 24, 2016·43 cites·22 claims
- 1595US8642742B2Anti-CEA antibodiesHOFER THOMAS U·Filed 2012·Granted Feb 4, 2014·38 cites·18 claims
- 1694US11332545B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2019·Granted May 17, 2022·6 cites·9 claims
- 1794US9068008B2Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereofMÖSSNER EKKEHARD·Filed 2010·Granted Jun 30, 2015·33 cites·25 claims
- 1894US9011847B2Anti-FAP antibodies and methods of useBACAC MARINA·Filed 2011·Granted Apr 21, 2015·34 cites·26 claims
- 1993US11591397B2Bispecific antibody molecules binding to CD3 and EGFRvIIIHOFFMANN LA ROCHE·Filed 2021·Granted Feb 28, 2023·2 cites·15 claims
- 2093US10781258B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Granted Sep 22, 2020·4 cites·39 claims
- 2193US10155815B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2014·Granted Dec 18, 2018·12 cites·46 claims
- 2292US12215155B2Antibodies binding to CD3 and CD19HOFFMANN LA ROCHE·Filed 2023·Granted Feb 4, 2025·1 cites·64 claims
- 2392US11608376B2Tumor-targeted agonistic CD28 antigen binding moleculesHOFFMANN LA ROCHE·Filed 2019·Granted Mar 21, 2023·14 cites·49 claims
- 2492US9963513B2Method for the selection of antibodies against BCMAENGMAB AG·Filed 2014·Granted May 8, 2018·19 cites·5 claims
- 2592US8945571B2Targeted immunoconjugatesMÖSSNER EKKEHARD·Filed 2010·Granted Feb 3, 2015·49 cites·24 claims
- 2690US11214622B2Antibodies specific for DR5 and methods of useROCHE GLYCART AG·Filed 2018·Granted Jan 4, 2022·6 cites·13 claims
- 2790US9926379B2Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5ROCHE GLYCART AG·Filed 2014·Granted Mar 27, 2018·17 cites·28 claims
- 2889US10562949B2Interleukin-2 fusion proteins and uses thereofROCHE GLYCART AG·Filed 2017·Granted Feb 18, 2020·6 cites·10 claims
- 2988US11098099B2Interleukin-2 fusion proteins and uses thereofHOFFMANN LA ROCHE·Filed 2015·Granted Aug 24, 2021·5 cites·28 claims
- 3088US10040843B2Interleukin-10 fusion proteins and uses thereofROCHE GLYCART AG·Filed 2016·Granted Aug 7, 2018·7 cites·22 claims
- 3188US9650442B2Bispecific anti-EGFR/anti IGF-1R antibodiesROCHE GLYCART AG·Filed 2014·Granted May 16, 2017·14 cites·6 claims
- 3287US10253104B2Bispecific antibodies against CD3ϵ and BCMAENGMAB AG·Filed 2015·Granted Apr 9, 2019·10 cites·16 claims
- 3386US11672858B2Bispecific antibody molecules binding to CD3 and TYRP-1HOFFMANN LA ROCHE·Filed 2019·Granted Jun 13, 2023·2 cites·16 claims
- 3486US2023365711A1Anti-cea antibodiesROCHE GLYCART AG·Filed 2023·Application pending·0 cites
- 3585US10781257B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Granted Sep 22, 2020·1 cites·34 claims
- 3684US12473373B2Bispecific antibody molecules binding to CD3 and EGFRvIIIHOFFMANN LA ROCHE·Filed 2023·Granted Nov 18, 2025·0 cites·30 claims
- 3784US11827711B2Antibodies binding to NKG2DHOFFMANN LA ROCHE·Filed 2020·Granted Nov 28, 2023·1 cites·27 claims
- 3884US10077315B2Bispecific antibodies against CD3 and BCMAENGMAB AG·Filed 2014·Granted Sep 18, 2018·6 cites·5 claims
- 3983US12286486B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2022·Granted Apr 29, 2025·0 cites·17 claims
- 4083US11365232B2Interleukin-2 fusion proteins and uses thereofROCHE GLYCART AG·Filed 2020·Granted Jun 21, 2022·1 cites·6 claims
- 4183US2023076791A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2022·Application pending·0 cites
- 4281US2022064296A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 4381US2025277035A1ANTIBODIES BINDING TO CD3 and CD19HOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 4480US10851171B2Method for the selection of antibodies against BCMAENGMAB SARL·Filed 2018·Granted Dec 1, 2020·1 cites·4 claims
- 4580US2023277662A1Antibodies binding to cd3HOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 4679US2022242971A1Novel immunoconjugatesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 4779US2022002441A1Anti-cea antibodiesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 4878US10584178B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 10, 2020·2 cites·6 claims
- 4978US2021253703A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 5078US2021253704A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
Showing the top 50 of 89 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →